Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Management of Medication Toxicity or Intolerance
Last Updated: April 16, 2019; Last Reviewed: April 16, 2019
|Adverse Effects||Associated ARVs||Onset/Clinical Manifestations||Estimated Frequency||Risk Factors||Prevention/ Monitoring||Management|
|Reported frequency varies with specific ARV regimen, duration of ART, and the specific laboratory parameters used to diagnose lipid abnormalities.
10% to 20% in young children receiving LPV/r.
40% to 75% of older children and adolescents with prolonged ART history will have lipid abnormalities.
Higher abnormal fasting serum lipids have been observed in ART-naive adults who received EVG/COBI/FTC/TAF than in those who received EVG/COBI/FTC/TDF.
Increase in serum lipids from baseline has also been noted in adolescents receiving EVG/COBI/FTC/TAF.
|Advanced-stage HIV disease
High-fat, high-cholesterol diet
Lack of exercise
Family history of dyslipidemia or premature CVD
Adolescents and Adults:
|Assess all patients for additional CVD risk factors. Patients living with HIV are considered to be at moderate risk of CVD.b
ART regimen changes should be considered, especially when the patient is receiving older PIs (e.g., LPV/r) and/or ritonavir boosting. Substituting a PI-sparing regimen, a PI-based regimen with a more favorable lipid profile, or COBI boosting causes a decline in LDL-C or TG values. However, the lipid-lowering effect for LDL-C is less pronounced than treatment results with statin therapy.
Refer patients to a lipid specialist early if LDL-C ≥250 mg/dL or TG ≥500 mg/dL.
If LDL-C is ≥130 mg/dL but <250 mg, or TG is ≥150 mg/dL but <500 mg/dL, a staged treatment approach is recommended by the NHLBI guidelines.b
|a Given the burden of collecting fasting blood samples, some practitioners routinely measure cholesterol and triglycerides from nonfasting blood samples and follow up abnormal values with a test done in the fasted state.
b Refer to the NHLBI guidelines: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents.
Key to Acronyms: ALT = alanine aminotransferase; ART = antiretroviral therapy; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; CK = creatine kinase; COBI = cobicistat; CVD = cardiovascular disease; DRV = darunavir; DRV/r = darunavir/ritonavir; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; FLP = fasting lipid profile; FTC = emtricitabine; HDL-C = high-density lipoprotein cholesterol; INSTI = integrase strand transfer inhibitor; LDL-C = low-density lipoprotein cholesterol; LFT = liver function test; LPV/r = lopinavir/ritonavir; NHLBI = National Heart, Lung, and Blood Institute; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PUFA = polyunsaturated fatty acid; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TC = total cholesterol; TDF = tenofovir disoproxil fumarate; TG = triglyceride
- Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics. 2007;119(2):370-380. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17272627.
- McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A, First Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the first pediatric switch study. Pediatrics. 2003;111(3):e275-281. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12612284.
- Vigano A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2005;10(8):917-924. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16430197.
- Tassiopoulos K, Williams PL, Seage GR 3rd, et al. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr. 2008;47(5):607-614. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18209684.
- Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS. 2009;23(6):661-672. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19279441.
- Rhoads MP, Lanigan J, Smith CJ, Lyall EG. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr. 2011;57(5):404-412. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21499114.
- Jacobson DL, Williams P, Tassiopoulos K, Melvin A, Hazra R, Farley J. Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. J Acquir Immune Defic Syndr. 2011;57(5):413-420. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21602698.
- O'Gorman CS, O'Neill MB, Conwell LS. Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag. 2011;7:1-14. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21339908.
- Dube MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab. 2011;25(3):429-442. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21663837.
- Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52(3):387-395. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21189273.
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Integrated guidelines for cardiovascular health and risk reduction in children and adolescents. The report of the expert panel. 2012. Available at: https://www.nhlbi.nih.gov/health-topics/integrated-guidelines-for-cardiovascular-health-and-risk-reduction-in-children-and-adolescents .
- Food and Drug Administration. FDA drug safety communication: interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293877.htm.
- Langat A, Benki-Nugent S, Wamalwa D, et al. Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age. Pediatr Infect Dis J. 2013;32(7):e298-304. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23385950.
- Casado JL, de Los Santos I, Del Palacio M, et al. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART. HIV Clin Trials. 2013;14(1):1-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23372109.
- Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. J Am Coll Cardiol. 2012;59(11):979-988. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22402068.
- Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;60(4):369-376. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22134152.
- Hazra R, Cohen RA, Gonin R, et al. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children. AIDS. 2012;26(2):235-240. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22008654.
- Arpadi S, Shiau S, Strehlau R, et al. Metabolic abnormalities and body composition of HIV-infected children on lopinavir or nevirapine-based antiretroviral therapy. Arch Dis Child. 2013;98(4):258-264. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23220209.
- Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc. 2013;16:18600. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23782481.
- Blazquez D, Ramos-Amador JT, Sainz T, et al. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis. 2015;15:119. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25880777.
- Bwakura-Dangarembizi M, Musiime V, Szubert AJ, et al. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Pediatr Infect Dis J. 2015;34(2):e23-31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25068287.
- Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. J Ped Endocrinol Metab. 2014;27(5-6):403-412. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24259240.
- Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. High prevalence of dyslipidemia and insulin resistance in HIV-infected pre-pubertal African children on antiretroviral therapy. Pediatr Infect Dis J. 2015. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26421804.
- Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606-2615. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25890673.
- Murnane P, Strehlau R, Shiau S, et al. Three-year outcomes in PMTCT-exposed children switched to EFV once suppressed on LPVr. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections. 2016. Boston, MA.
- Lee FJ, Monteiro P, Baker D, et al. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial. HIV Med. 2016;17(8):605-614. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26987376.
- Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a Phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4(7):e284-e294. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28416195.
- Ramteke SM, Shiau S, Foca M, et al. Patterns of growth, body composition, and lipid profiles in a South African cohort of human immunodeficiency virus-infected and uninfected children: a cross-sectional study. J Pediatric Infect Dis Soc. 2017. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28481997.
- Melvin AJ, Montepiedra G, Aaron L, et al. Safety and efficacy of atorvastatin in human immunodeficiency virus-infected children, adolescents and young adults with hyperlipidemia. Pediatr Infect Dis J. 2017;36(1):53-60. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27749649.
- Jao J, Yu W, Patel K, et al. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med. 2018;19(3):175-183. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29159965.
- Echecopar-Sabogal J, D'Angelo-Piaggio L, Chaname-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis. Int J STD AIDS. 2018;29(5):443-452. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28956700.
- Echeverria P, Bonjoch A, Puig J, Ornella A, Clotet B, Negredo E. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. HIV Med. 2017;18(10):782-786. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28671337.
- Vieira ADS, Silveira G. Effectiveness of n-3 fatty acids in the treatment of hypertriglyceridemia in HIV/AIDS patients: a meta-analysis. Cien Saude Colet. 2017;22(8):2659-2669. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28793080.